- FDACS approves first registration of Invaio's Trecise™
technology to deliver ArborBiotic™ for the suppression of citrus
greening in oranges
- Citrus growers gain new solution for the protection of young
and non-bearing trees
- Trecise™ technology is a gamechanger for disease treatment and
yield recovery
CAMBRIDGE, Mass., Aug. 29,
2023 /PRNewswire/ -- Invaio Sciences, a bio platform
company accelerating the leap to nature-positive agriculture, today
announced that its Citrus Health solution to suppress citrus
greening in oranges received approval from the Florida Department
of Agriculture and Community Services (FDACS) under section 24(c)
of the Federal Insecticide, Fungicide and Rodenticide Act
(FIFRA).
Invaio's Citrus Health solution treats the devastating citrus
greening disease – also known as Huanglongbing (HLB) – spread by
the Asian citrus psyllid. The disease has wreaked havoc on the
Florida citrus industry and is
responsible for massive losses in yields and profits since
2006.
"I'm really excited about what Invaio is doing," said
Ned Hancock, Fifth-Generation Citrus
Grower. "This is probably the first time in my lifetime our
industry has seen truly new technology. I see this as potentially
revolutionizing the way we manage citrus."
Invaio's new solution will deliver
ArborBiotic™1 through Invaio's groundbreaking
application technology, Trecise™. Unlike conventional injection
treatments, this minimally invasive system requires 90% less active
ingredient as it delivers directly into the tree's vascular system.
Trials of the solution have shown an average yield increase of 30%
after just one treatment as well as increased in BRIX and a
reduction in fruit drop.
"Invaio's Trecise™ technology offers a real breakthrough in the
fight against citrus greening, a disease that has devastated the
industry for more than 15 years," said Ignacio Martinez, Founding CEO of Invaio. "This
is the first of many Invaio technologies that will benefit growers,
crops and the environment."
The Trecise™ system has several key advantages for growers and
applicators. Its 120-day pre-harvest interval is 60 days shorter
than conventional injection treatments. There's no need for
drilling, making it suitable for young trees that have had few
treatment options available until now. Because it applies active
ingredients directly in the conductive tissues of the tree, it
needs lower rates for equivalent efficacy, reducing the risks of
misapplication and residues. It also dramatically reduces risk of
exposure to workers and the environment because of its
closed-system design.
"We're excited to launch our Trecise™ system and are optimistic
about the future of Florida's
citrus industry. With our initial focus on treating young and
non-bearing trees, we hope to show that growers can get trees to
bearing age with minimal disease symptoms and build confidence for
replanting," said Dave Gerrard, Head
of Commercial US. "This is just the first step. We're committed to
delivering further solutions to help Florida citrus growers regain their pre-HLB
yields."
About Invaio
Invaio Sciences, founded by Flagship
Pioneering, is a bio platform company accelerating the leap to
nature-positive agriculture. The company builds on advances in
human health and digital innovation to develop biological
technologies for crop health, enabling farmers to both improve
yields and use more natural crop health solutions. Invaio is
addressing consumer demands and unlocking radical benefits for
farmers and the environment, leaving every acre better today and
for generations to come. For more information about Invaio, please
visit www.invaio.com or follow Invaio
on Twitter or LinkedIn. For more information about
Invaio Citrus Health in the US, visit www.invaiocitrus.com
About Flagship Pioneering
Flagship
Pioneering conceives, creates, resources, and develops
first-in-category bioplatform companies to transform human health
and sustainability. Since its launch in 2000, the firm has, through
its Flagship Labs unit, applied its unique hypothesis-driven
innovation process to originate and foster more than 100 scientific
ventures, resulting in more than $90
billion in aggregate value. To date, Flagship has deployed
over $3.4 billion in capital toward
the founding and growth of its pioneering companies alongside more
than $26 billion of follow-on
investments from other institutions. The current Flagship ecosystem
comprises 45 transformative companies, including Denali
Therapeutics (NASDAQ: DNLI), Foghorn Therapeutics
(NASDAQ: FHTX), Generate Biomedicines, Inari, Indigo
Agriculture, Moderna (NASDAQ: MRNA), Omega Therapeutics
(NASDAQ: OMGA), Sana Biotechnology (NASDAQ: SANA), Seres
Therapeutics (NASDAQ: MCRB) and Tessera Therapeutics.
1ArborBiotic™ is a trademark of MGF Scientific,
Inc.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/invaio-achieves-first-registration-for-citrus-greening-solution-featuring-trecise-technology-301912468.html
SOURCE Invaio Sciences